Our latest webinar starts on Tuesday 26 January at 18:00. We are joined by guest speakers from Orosur Mining, Savannah Resources, Rainbow Rare Earths and Goldplat. Register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7,897.00
Bid: 7,870.00
Ask: 7,872.00
Change: 120.00 (1.54%)
Spread: 2.00 (0.03%)
Open: 7,867.00
High: 7,947.00
Low: 7,804.00
Yest. Close: 7,777.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Trials For AstraZeneca's Covid-19 Treatment Set To Begin In UK

Sat, 21st Nov 2020 10:51

(Alliance News) - The UK will be the first country to begin clinical trials of a new coronavirus antibody treatment developed by drugs giant AstraZeneca PLC aimed at people with a weakened immune system who cannot be vaccinated.

A participant in Manchester will be the first in the world to receive the pharmaceutical company's new "antibody cocktail" as part of the trial to test whether it will prevent Covid-19 for up to year.

The clinical trial programme will recruit 5,000 participants, which includes 1,000 people from nine sites in the UK.

The aim of the trial is to evaluate the safety and effectiveness of a combination of two long-acting monoclonal antibodies – man-made proteins that act like natural human antibodies in the immune system.

Mene Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca, said the treatment, which can be injected or administered intravenously, is aimed at those who have a weakened immune system and cannot be vaccinated as well as those who are unlikely to respond to immunisation – which may include hundreds of thousands people in the UK.

He said: "There is going to be a significant number of people – even in a world where vaccines are highly effective – who will not respond to vaccines, or in fact will not take vaccines.

"So having monoclonal antibodies as potential therapeutics is also important."

The UK government has an in-principle agreement to secure access to one million doses of the antibody combination, dubbed AZD7442, if it is successful in the phase three trials.

The trial aims to enrol adults who are at increased risk of Covid-19 infection or who are more likely to have an inadequate response to vaccination, and will include people from health care and care home settings.

Pangalos said: "We need people to sign up to this [trial], particularly those vulnerable people over 60 who are immuno-suppressed, and may be at higher risk of developing severe disease."

Initial results from the randomised control trial are expected to be published in the first half of 2021, although the trial is expected to last for 12 months.

Kate Bingham, chairwoman of the UK's Vaccine Taskforce, said: "This is part of the portfolio to protect the whole UK.

"So, obviously, vaccines work in people who have a functional immune system.

"[But] if you are immuno-suppressed and you are going through bone marrow transplants, or indications or treatments that actually reduce your ability to mount an immune response, then this is basically the only current way of providing that short-term passive immunity.

"So we are absolutely looking to protect those people who are immuno-suppressed or those people who need immediate protection, because you will remember that vaccines typically take about six weeks to work."

She said the NHS Vaccine Research Registry – a list of 340,000 volunteers willing to go into clinical trials – will provide some patients for the trial.

Pangalos said the two antibodies have been engineered with a life-extension technology to make them effective for a longer period of time.

He said: "We think they will confer protection for between six, but more likely closer to 12 months, which makes them in effect, almost like a passive vaccination."

Whilst it is unclear how much the antibody treatment will cost, Pangalos said it will be "more expensive than vaccines", but added "we hope to make it cost effective".

Business Secretary Alok Sharma said: "I am very proud that the UK is the first country in the world to begin this invaluable study, and that a fifth of trial volunteers will be from Britain – a testament to our fantastic life sciences sector and the willingness of our people to come forward to help others.

"As we move closer to a Covid-19 vaccine, we must keep driving forward clinical trials for new and alternative treatments that protect our vulnerable, particularly those who cannot receive a vaccine.

"That is why we have procured one million doses of AstraZeneca's long-acting antibody treatment if it meets robust safety and effectiveness standards."

By Nilima Marshall, PA Science Reporter

source: PA

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

GLOBAL MARKETS-Stocks lag, dollar advances on COVID-19 concerns

By Matt ScuffhamNEW YORK, Jan 25 (Reuters) - Global stocks lagged and the dollar advanced in volatile markets on Monday, with sentiment hit by increasing COVID-19 cases, delays in vaccine supplies and uncertainty over a $1.9 trillion U.S. stimulus...

Today 20:30

Germany fears AstraZeneca vaccine won't get EU approval for those over 65 -Bild

FRANKFURT, Jan 25 (Reuters) - AstraZeneca's COVID-19 vaccine is not very effective for people over 65, German coalition sources told tabloid Bild and Handelsblatt, a step which calls into question its suitability in mass vaccination programmes.Ger...

Today 20:22

UPDATE: EU Warns AstraZeneca Over Vaccine Delivery Delay

UPDATE: EU Warns AstraZeneca Over Vaccine Delivery Delay

Today 19:15

Difficult to put timeline on lockdown easing- UK minister

LONDON, Jan 25 (Reuters) - It is difficult to put a timelime on easing lockdown measures, Britain's health minister said on Monday, adding that the government will look at the death rate, the number of hospitalisations, variants and the success of...

Today 17:25

UK health minister says new COVID variant makes it harder to lift lockdown

LONDON, Jan 25 (Reuters) - Britain's health minister Matt Hancock said on Monday a new more infectious coronavirus variant means the government needs to be more cautious in lifting lockdown restrictions.The government said on Friday that the new v...

Today 17:13

TOP NEWS: EU Slams AstraZeneca Vaccine Delay, Urges Transparency

TOP NEWS: EU Slams AstraZeneca Vaccine Delay, Urges Transparency

Today 17:11

EU says AstraZeneca's explanation of decision to slow COVID-19 vaccine supplies inadequate -EU commissioner

BRUSSELS, Jan 25 (Reuters) - The European Union health commissioner said that AstraZeneca had provided insufficient clarification at a meeting on Monday to its decision to slow down supplies of COVID-19 vaccines to the EU.Stella Kyriakides said th...

Today 16:42

TOP NEWS: AstraZeneca Boss Denounces "Me First" Approach To Covid Jabs

TOP NEWS: AstraZeneca Boss Denounces "Me First" Approach To Covid Jabs

Today 14:45

Projected UK Pfizer vaccine supply unchanged for Jan to March period - PM's spokesman

LONDON, Jan 25 (Reuters) - The total projected amount of Pfizer coronavirus vaccine supplied to Britain between January and March will be unchanged by a planned upgrade at a production facility, Prime Minister Boris Johnson's spokesman said on Mo...

Today 12:58

EU to require advance registration of COVID-19 vaccine exports

BRUSSELS, Jan 25 (Reuters) - The European Union will require pharmaceutical companies producing COVID-19 vaccines inside the bloc to register in advance any exports of doses to third countries, an EU official said on Monday.The move comes after As...

Today 12:23

UPDATE 1-EU seeks answers from AstraZeneca on cut to vaccine supplies

* AstraZeneca asked for further clarification* EU paid 336 mln euros to boost Astra's production capacity* Astra was obliged to start production in Oct. - lawmaker (adds EU spokesman, official, lawmaker)By Francesco Guarascio and Sabine SieboldBRUSS...

Today 11:29

UPDATE 2-EU urges AstraZeneca to find ways to speed up vaccine supplies

* EU to require pre-registration of COVID vaccine exports -source* AstraZeneca asked for further clarification after sudden cut* EU paid 336 mln euros to boost Astra's production capacity* Astra was required to start production in October - lawmak...

Today 11:29

UPDATE 3-EU urges AstraZeneca to speed up vaccine supplies amid 'supply shock'

* EU to require pre-registration of COVID vaccine exports -source* AstraZeneca asked for further clarification after sudden cut* EU paid 336 mln euros to boost Astra's production capacity* Australia, Thailand say Astra has told them of cut to supp...

Today 11:29

UPDATE 3-EU urges AstraZeneca to speed up vaccine deliveries amid 'supply shock'

* EU to require pre-registration of COVID vaccine exports -source* AstraZeneca asked for further clarification after sudden cut* EU paid 336 mln euros to boost Astra's production capacity* Australia, Thailand say Astra has told them of cut to supp...

Today 11:29

UPDATE 4-EU locks horns with AstraZeneca on vaccine deliveries amid 'supply shock'

* EU to require pre-registration of COVID vaccine exports* AstraZeneca did not offer adequate clarification after cut- EU* EU paid 336 mln euros to boost Astra's production capacity* Australia, Thailand say Astra has told them of cut to supplies (...

Today 11:29

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.